Glenmark 'pioneers' Mitsubishi's teneligliptin in India
This article was originally published in Scrip
Executive Summary
Brace yourselves for a potential upsurge in action – both in price and probably elsewhere - in the dipeptidyl peptidase-4 (DPP-4) inhibitor segment in India.
You may also be interested in...
Januvia Generics Arrive In India
A wave of cut-price sitagliptin generics is seen hitting the Indian market with expiry of the patent on Merck’s Januvia, a product that has had a hugely eventful journey over the years including fending off pre-expiry challengers. Will the originator respond with price cuts?
Januvia Generics Arrive: Can MSD Defend Its Turf In India?
A wave of cut-price sitagliptin generics is seen hitting the Indian market with expiry of the patent on Merck’s Januvia, a product that has had a hugely eventful journey over the years including fending off pre-expiry challengers. Will the company respond with price cuts?
Mitsubishi Takes Teneligliptin Patent Appeal To Indian Court
Japan's Mitsubishi Tanabe has moved a court against Indian patent authorities in a case concerning its patent application relating to certain salts of teneligliptin. The move has set the cat among the pigeons in the Indian market, where cut price versions of the diabetes drug have made strong gains over the recent past, though it's still unclear if the salt patent may have a bearing on these.